Page 7 - ஏ நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஏ நிதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஏ நிதி Today - Breaking & Trending Today
Fidelity leads $100m Series C round in China-based clinical CRO dMed Source: Volodymyr Hryshchenko/Unsplash Premium dMed Biopharmaceutical, a clinical contract research organisation (CRO) with operations in China and the US, announced on Thursday that it has raised $100 million in a Series C round of financing led by Fidelity Management & Research Company. Continue reading this story with a subscription to DealStreetAsia. Contact us for corporate subscriptions at [email protected]. Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday REGISTER stories left placeholder You have one free story left this month. ....
Regency Centers Invites You to Join Its Fourth Quarter 2020 Earnings Conference Call Regency Centers Invites You to Join Its Fourth Quarter 2020 Earnings Conference Call JACKSONVILLE, Fla., Dec. 16, 2020 Regency Centers Corporation (The “Company”) (NASDAQ: REG) will announce its Fourth Quarter 2020 earnings results on Thursday, February 11, 2021, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Friday, February 12, 2021, at 12:00 p.m. ET. Fourth Quarter 2020 Earnings Conference Call Date: About Regency Centers Corporation (NASDAQ: REG) ....
dMed, a Shangai, China-based clinical CRO, completed a US$100m Series C financing. The round was led by Fidelity Management & Research Company, LLC, with participation from new investors Sequoia Capital China, Kaiser Foundation Hospitals and E Fund, and existing backers Qiming Venture Partners, Lilly Asia Ventures, and Vivo Capital. Led by Founder, Chairman and CEO, Dr. Lingshi Tan, dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. The company leverages and integrates China’s new regulatory framework to offer innovative drug development strategies, and help clients expand globally by tapping into the world’s second largest pharmaceutical market. Its collaboration models will help Chinese and global innovative pharma companies raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rate. ....
dMed Completed a US$100 Million Series C Financing News provided by Share this article Share this article SHANGHAI, Dec. 17, 2020 /PRNewswire/ dMed, the clinical CRO with strong presence in China and the US, the world s two largest pharmaceutical markets and drug development sites, announced today its successful completion of a US$100 million Series C financing. Led by Fidelity Management & Research Company, LLC, new investors in dMed include Sequoia Capital China, Kaiser Foundation Hospitals and E Fund. They now join the leaders in dMed s angel, A and B rounds, Qiming Venture Partners, Lilly Asia Ventures, and Vivo Capital, which have taken most of the opportunities to increase their contributions to dMed s capital since the company s inception in 2016. ....
Զինծառայողների ապահովագրության հիմնադրամի տնօրենը այլընտրանքի չի տեսնում․ 1000 դրամները պետք է 3000 դառնան azatutyun.am - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from azatutyun.am Daily Mail and Mail on Sunday newspapers.